Quick Ratio: Rein Therapeutics Inc (RNTX)

Rein Therapeutics Inc (RNTX) develops peptides to protect healthy cells during chemotherapy, which will grant the company full pricing power upon clinical success, with the indicator standing at 4.21. This price chart on GURU.Markets clearly demonstrates and confirms this potential. The company is implementing energy saving and emission filtration in its laboratories, while a shift in development focus creates a volatile risk profile.

The quick ratio assesses the issuer's ability to settle short-term debts using its most liquid assets, completely excluding illiquid inventories from the calculation. By analyzing the quick liquidity chart, an investor determines the margin of safety for Rein Therapeutics Inc (RNTX) in the absence of revenue, where business scaling is reduced to rising clinical trial costs without operating leverage.